Statistics for Recursion Pharmaceuticals, (id:7763 RXRX)

Valuation metrics

Market cap

1.98B

Enterprise value

1.43B

Trailing P/E (ttm)

-3.61

Forward P/E

-3.57

PEG ratio

-3.57

Price/Sales (ttm)

30.39

Price/Book (mrq)

3.37

Enterprise Value/Revenue

22.00

Enterprise Value/EBITDA

-3.94

Overview

Shares outstanding

279.60M

Float

252.42M

Shares short

62.43M

% Held by insiders

0.05%

% Held by institutions

0.94%

Average volume (10 days)

7.36M

Average volume (90 days)

Price summary

52-Week low

5.60

52-Week high

15.74

52-Week change

-14.56%

Beta

0.80

50-Day moving average

6.65

200-Day moving average

8.41

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

2.94%

Operating margin

-377.10%

Operational effectiveness

Return on assets

-36.40%

Return on equity

-78.49%

Income statement

Revenue (ttm)

0.26

Revenue per share (ttm)

0.26

Quarterly revenue growth (yoy)

Gross profit (ttm)

1.29M

EBITDA

-364,150,016.00

Net income to common (ttm)

-377,751,008.00

Diluted EPS (ttm)

-1.38

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

427.65M

Total cash per share (mrq)

1.49

Total debt (mrq)

90.62M

Total Debt/Equity (mrq)

17.28

Current ratio (mrq)

435.50%

Book value per share (mrq)

1.83

Cash flow

Cash flow statement

-317,820,992.00

Levered free cash flow (LFCF)

-186,334,368.00